ATE235513T1 - Opioid-konjugate mit endogenen trägerproteinen - Google Patents

Opioid-konjugate mit endogenen trägerproteinen

Info

Publication number
ATE235513T1
ATE235513T1 AT01121557T AT01121557T ATE235513T1 AT E235513 T1 ATE235513 T1 AT E235513T1 AT 01121557 T AT01121557 T AT 01121557T AT 01121557 T AT01121557 T AT 01121557T AT E235513 T1 ATE235513 T1 AT E235513T1
Authority
AT
Austria
Prior art keywords
patient
conjugates
antinociceptive
conjugate
vivo
Prior art date
Application number
AT01121557T
Other languages
English (en)
Inventor
Alan M Ezrin
Dominique P Bridon
Darren L Holmes
Peter Milner
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Application granted granted Critical
Publication of ATE235513T1 publication Critical patent/ATE235513T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT01121557T 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen ATE235513T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
ATE235513T1 true ATE235513T1 (de) 2003-04-15

Family

ID=22057753

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01121557T ATE235513T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen
AT98956656T ATE216402T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98956656T ATE216402T1 (de) 1997-11-07 1998-11-06 Opioid-konjugate mit endogenen trägerproteinen

Country Status (9)

Country Link
EP (2) EP1007561B1 (de)
JP (2) JP2001522817A (de)
AT (2) ATE235513T1 (de)
AU (3) AU750387B2 (de)
CA (2) CA2301799C (de)
DE (2) DE69812727D1 (de)
ES (1) ES2173641T3 (de)
IL (1) IL135835A0 (de)
WO (3) WO1999024076A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1179012B2 (de) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP1171582A2 (de) * 1999-05-17 2002-01-16 Conjuchem, Inc. Lang wirksame antiangiogene peptide
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
AU765753B2 (en) * 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
CA2435563A1 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
CA2526907C (en) 2003-01-17 2012-11-13 Advanced Proteome Therapeutics, Inc. Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
ES2347902T3 (es) 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
EP1773400A2 (de) 2004-07-08 2007-04-18 Amgen Inc. Therapeutische peptide
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2114437A2 (de) 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modifizierte peptide mit corticotropinfreisetzungsfaktor und verwendungen davon
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
KR20170051414A (ko) * 2014-07-18 2017-05-11 바이오코젠트, 엘엘씨 살리실레이트 및 폴리살리실레이트를 포함하는 조성물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59138958A (ja) * 1983-01-31 1984-08-09 Mitsubishi Chem Ind Ltd 抗血清
US4784955A (en) * 1984-09-21 1988-11-15 Miles Inc. Immunogen conjugates and the use thereof in a dihydropyridine assay
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
DK608589D0 (da) * 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
JPH04364200A (ja) * 1991-06-10 1992-12-16 Unitika Ltd 細胞接着性アルブミン
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes

Also Published As

Publication number Publication date
JP2001522817A (ja) 2001-11-20
AU1519799A (en) 1999-05-31
CA2301799C (en) 2007-08-07
WO1999024074A3 (en) 1999-08-19
IL135835A0 (en) 2001-05-20
CA2309205A1 (en) 1999-05-20
JP2001522863A (ja) 2001-11-20
DE69812727D1 (de) 2003-04-30
WO1999024076A2 (en) 1999-05-20
WO1999024462A2 (en) 1999-05-20
EP1028971A2 (de) 2000-08-23
WO1999024462A3 (en) 1999-08-26
AU1385699A (en) 1999-05-31
DE69804974T2 (de) 2002-11-07
EP1007561A2 (de) 2000-06-14
ES2173641T3 (es) 2002-10-16
WO1999024076A3 (en) 1999-08-19
CA2301799A1 (en) 1999-05-20
AU750387B2 (en) 2002-07-18
WO1999024074A2 (en) 1999-05-20
EP1007561B1 (de) 2002-04-17
DE69804974D1 (de) 2002-05-23
AU1312799A (en) 1999-05-31
WO1999024076A9 (en) 2000-06-08
ATE216402T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
ATE216402T1 (de) Opioid-konjugate mit endogenen trägerproteinen
Ringsdorf Structure and properties of pharmacologically active polymers
CA2064689A1 (en) Stabilized protein or peptide conjugates
ATE142506T1 (de) Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin- technologie
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
WO1988000834A1 (en) Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
Poznansky et al. Insulin: carrier potential for enzyme and drug therapy
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
US5411943A (en) Hepatoma treatment with somatostatin analogs
Habberfield et al. Vitamin B12-mediated uptake of erythropoietin and granulocyte colony stimulating factor in vitro and in vivo
AU2002238687B2 (en) Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
Basu et al. Enhanced intracellular delivery of doxorubicin by scavenger receptor‐mediated endocytosis for preferential killing of histiocytic lymphoma cells in culture
IL117564A (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
TH55748A (th) การใช้อินเทอร์เฟรอน-เบต้าในการบำบัดรักษาของเนื้องอกประเภทของอีวิง
Wheeler RG-1068 RepliGen
Squibb INTROS
ITMI960133A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento di disfunzioni erettili
MD1135F1 (en) Paradontium treatment method
CA2326720A1 (en) Hemoglobin-haptoglobin complexes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties